DOI QR코드

DOI QR Code

A Comprehensive Analysis of the Association of Psoas and Masseter Muscles with Traumatic Brain Injury Using Computed Tomography Anthropometry

  • Cho, Hang Joo (Department of Trauma Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Hwang, Yunsup (Department of Radiology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Yang, Seiyun (Department of Neurourgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Maru (Department of Trauma Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2021.01.04
  • Accepted : 2021.03.10
  • Published : 2021.11.01

Abstract

Objective : Psoas and masseter muscles are known markers of sarcopenia. However, the relative superiority of either muscle as a marker is unclear. Therefore, this study analyzed the two muscles in patients with a prognosis of traumatic brain injury (TBI). Methods : Patients with TBI visiting a regional trauma center between January 2017 and December 2018 were selected, and their medical records were reviewed. TBI patients with an abbreviated injury score (AIS) of 4 or 5 were selected. Patients with an AIS of 4 or 5 at the chest, abdomen, and extremity were excluded. Patients with a hospital stay of 1 to 2 days were excluded. Both muscle areas were measured based on the initial computed tomography. The psoas muscle index (PMI) and the masseter muscle index (MMI) were calculated by dividing both muscle areas by height in meters squared (cm2/m2). These muscle parameters along with other medical information were used to analyze mortality and the Glasgow outcome scale (GOS). Results : A total of 179 patients, including 147 males (82.1%), were analyzed statistically. The mean patient age was 58.0 years. The mortality rate was 16.8% (30 patients). The mean GOS score was 3.7. Analysis was performed to identify the parameters associated with mortality, which was a qualitative study outcome. The psoas muscle area (16.9 vs. 14.4 cm2, p=0.028) and PMI (5.9 vs. 5.1 cm2/m2, p=0.004) showed statistical differences between the groups. The PMI was also statistically significant as a risk factor for mortality in logistic regression analysis (p=0.023; odds ratio, 0.715; 95% confidence interval, 0.535-0.954). Quantitative analyses were performed with the GOS scores. Bivariate correlation analysis showed a statistically significant correlation between PMI and GOS scores (correlation coefficient, 0.168; p=0.003). PMI (p=0.004, variation inflation factor 1.001) was significant in multiple regression analysis. The masseter muscle area and MMI did not show significance in the study. Conclusion : Larger PMI was associated with statistically significant improved survival and GOS scores, indicating its performance as a superior prognostic marker. Further analyses involving a larger number of patients, additional parameters, and more precise settings would yield a better understanding of sarcopenia and TBI.

Keywords

Acknowledgement

The authors wish to acknowledge the financial support of the Catholic Medical Center Research Foundation made in the program year of 2019.

References

  1. Anker SD, Morley JE, von Haehling S : Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle 7 : 512-514, 2016 https://doi.org/10.1002/jcsm.12147
  2. Baracos VE : Psoas as a sentinel muscle for sarcopenia: a flawed premise. J Cachexia Sarcopenia Muscle 8 : 527-528, 2017 https://doi.org/10.1002/jcsm.12221
  3. Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. : Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle 8 : 238-244, 2017 https://doi.org/10.1002/jcsm.12149
  4. Bone AE, Hepgul N, Kon S, Maddocks M : Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis 14 : 85-99, 2017 https://doi.org/10.1177/1479972316679664
  5. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. : Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48 : 16-31, 2019 https://doi.org/10.1093/ageing/afy169
  6. Cruz-Jentoft AJ, Sayer AA : Sarcopenia. Lancet 393 : 2636-2646, 2019 https://doi.org/10.1016/s0140-6736(19)31138-9
  7. Damluji AA, Rodriguez G, Noel T, Davis L, Dahya V, Tehrani B, et al. : Sarcopenia and health-related quality of life in older adults after trans-catheter aortic valve replacement. Am Heart J 224 : 171-181, 2020 https://doi.org/10.1016/j.ahj.2020.03.021
  8. Davis MP, Panikkar R : Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med 8 : 86-101, 2019 https://doi.org/10.21037/apm.2018.08.02
  9. De Buyser SL, Petrovic M, Taes YE, Toye KR, Kaufman JM, Lapauw B, et al. : Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing45 : 602-608, 2016 https://doi.org/10.1093/ageing/afw071
  10. Drudi LM, Phung K, Ades M, Zuckerman J, Mullie L, Steinmetz OK, et al. : Psoas muscle area predicts all-cause mortality after endovascular and open aortic aneurysm repair. Eur J Vasc Endovasc Surg 52 : 764-769, 2016 https://doi.org/10.1016/j.ejvs.2016.09.011
  11. Gilligan LA, Towbin AJ, Dillman JR, Somasundaram E, Trout AT : Quantification of skeletal muscle mass: sarcopenia as a marker of overall health in children and adults. Pediatr Radiol 50 : 455-464, 2020 https://doi.org/10.1007/s00247-019-04562-7
  12. Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Hammad A, Tamai Y, et al. : Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition 32 : 1200-1205, 2016 https://doi.org/10.1016/j.nut.2016.04.003
  13. Hu P, Uhlich R, White J, Kerby J, Bosarge P : Sarcopenia measured using masseter area predicts early mortality following severe traumatic brain lijury. J Neurotrauma 35 : 2400-2406, 2018 https://doi.org/10.1089/neu.2017.5422
  14. Hwang Y, Lee YH, Cho DH, Kim M, Lee DS, Cho HJ : Applicability of the masseter muscle as a nutritional biomarker. Medicine (Baltimore) 99 : e19069, 2020 https://doi.org/10.1097/md.0000000000019069
  15. Lee SJ, Park YJ, Cartmell KB : Sarcopenia in cancer survivors is associated with increased cardiovascular disease risk. Support Care Cancer 26 : 2313-2321, 2018 https://doi.org/10.1007/s00520-018-4083-7
  16. Lindstrom I, Protto S, Khan N, Hernesniemi J, Sillanpaa N, Oksala N : Association of masseter area and radiodensity with three-month survival after proximal anterior circulation occlusion. J Neurointerv Surg 13 : 25-29, 2021 https://doi.org/10.1136/neurintsurg-2020-015837
  17. Oksala NKJ, Lindstrom I, Khan N, Pihlajaniemi VJ, Lyytikainen LP, Pienimaki JP, et al. : Pre-operative masseter area is an independent predictor of long-term survival after carotid endarterectomy. Eur J Vasc Endovasc Surg 57 : 331-338, 2019 https://doi.org/10.1016/j.ejvs.2018.11.011
  18. Tanabe C, Reed MJ, Pham TN, Penn K, Bentov I, Kaplan SJ : Association of brain atrophy and masseter sarcopenia with 1-year mortality in older trauma patients. JAMA Surg 154 : 716-723, 2019 https://doi.org/10.1001/jamasurg.2019.0988
  19. Toptas M, Yalcin M, Akkoc I, Demir E, Metin C, Savas Y, et al. : The relation between sarcopenia and mortality in patients at intensive care unit. Biomed Res Int 2018 : 5263208, 2018
  20. Vellas B, Fielding RA, Bens C, Bernabei R, Cawthon PM, Cederholm T, et al. : Implications of ICD-10 for sarcopenia clinical practice and clinical trials: report by the international conference on frailty and sarcopenia research task force. J Frailty Aging 7 : 2-9, 2018
  21. Wallace JD, Calvo RY, Lewis PR, Brill JB, Shackford SR, Sise MJ, et al. : Sarcopenia as a predictor of mortality in elderly blunt trauma patients: comparing the masseter to the psoas using computed tomography. J Trauma Acute Care Surg 82 : 65-72, 2017 https://doi.org/10.1097/TA.0000000000001297